By Chidinma Chukwu, Abuja
The Federal Government has unveiled new financing initiatives and strategic investments to boost local pharmaceutical manufacturing, reduce dependence on imported medicines and improve access to affordable healthcare.
The National Coordinator of the Presidential Initiative for the Development of the Pharmaceutical Industry (PVAC), Dr. Mukhtar Abdul, disclosed this at the 2026 Joint Annual Review, where he highlighted progress in domestic drug production, industrial expansion and regional pharmaceutical collaboration.
Abdul said the government had introduced the Bridge to Scale financing mechanism, a donor-supported initiative designed to reduce borrowing costs and provide affordable financing for pharmaceutical manufacturers and businesses across the healthcare value chain.
He noted that Nigeria’s pharmaceutical manufacturing model was attracting interest from other African countries seeking to establish similar frameworks.
According to him, the initiative is also facilitating cross-border investments and partnerships involving Nigerian manufacturers and regulatory institutions.
Among the achievements recorded, Abdul listed the commencement of local production of long-lasting insecticide-treated nets, the establishment of diagnostic product packaging and manufacturing facilities, expansion of medical oxygen production capacity and investments in advanced pharmaceutical manufacturing.
He also disclosed that a major pharmaceutical company was preparing to establish an active pharmaceutical ingredient (API) manufacturing plant, with operations expected to commence in the first quarter of 2027.
“The initiative is also supporting cross-border investment and partnerships, including efforts to facilitate the establishment of pharmaceutical manufacturing facilities in other African countries, with the involvement of Nigerian manufacturers and regulatory institutions,” Abdul said.
He described the planned API facility as a significant milestone that could strengthen Nigeria’s pharmaceutical manufacturing capacity and position the country as a major player in Africa’s pharmaceutical industry.
The PVAC coordinator reaffirmed the initiative’s commitment to supporting more than 200 pharmaceutical manufacturing companies, while expanding financing opportunities for small and medium-sized enterprises in the healthcare sector.
He said the proposed Life Care Fund would provide an additional financing window for businesses, while sustained collaboration with regulatory agencies and industry stakeholders would support Nigeria’s ambition to attain a higher World Health Organisation (WHO) regulatory maturity status and advance local vaccine manufacturing.
Meanwhile, the National Agency for Food and Drug Administration and Control (NAFDAC) said it had intensified its campaign against counterfeit, substandard and falsified medicines, recording thousands of enforcement activities during the period under review.
The Director-General of NAFDAC, Prof. Mojisola Adeyeye, represented by Mr. Salihu Bello, disclosed that the agency conducted 5,532 enforcement activities, comprising 213 raids, 211 sanctions and 52 arrests.
According to the agency, it also seized 821 products, shut down 179 premises and destroyed counterfeit and expired products valued at ₦22.73 billion through 22 destruction exercises.
On its regulatory achievements, NAFDAC highlighted Nigeria’s attainment of full membership of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, making the country the organisation’s 24th member.
The agency also disclosed that Nigeria had become the 31st African Union member state to ratify and deposit its instrument of ratification for the African Medicines Agency agreement, a development expected to strengthen the country’s role in continental pharmaceutical regulation.

No comments yet. Start the conversation.